deltatrials
Unknown PHASE4 NCT00157378

Optimization of Acute Treatment in First Episode Schizophrenia

Optimization of Acute Treatment in First Episode Schizophrenic Patients by New Pharmacological Treatments

Sponsor: Department of Psychiatry University FU Berlin

Conditions Schizophrenia, First-Episode
Interventions Risperidone, Haloperidol
Updated 4 times since 2017 Last updated: Sep 8, 2005 Started: Nov 30, 2000 Completion: Dec 31, 2004

A PHASE4 clinical study on Schizophrenia, First-Episode, this trial is ongoing. The trial is conducted by Department of Psychiatry University FU Berlin and has accumulated 4 data snapshots since 2000. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE4

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE4

  4. Jan 2017 — Jan 2021 [monthly]

    Unknown Status PHASE4

    First recorded

Nov 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Department of Psychiatry University FU Berlin
  • Department of Psychiatry University of Bonn
  • German Research Network On Schizophrenia
  • Heinrich-Heine University, Duesseldorf
  • Janssen-Cilag Ltd.
  • Ludwig-Maximilians - University of Munich
  • Mainz University
  • Martin-Luther-Universität Halle-Wittenberg
  • RWTH Aachen University
  • University Hospital Tuebingen
  • University of Cologne
  • University of Göttingen
  • University of Jena
  • University of Mannheim
  • University of Wuerzburg
  • Universität Duisburg-Essen
Data source: Ludwig-Maximilians - University of Munich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Munich, Germany